Nontuberculous Mycobacteria Market

ID: MRFR/HC/14643-HCR 128 Pages Vikita Thakur Last Updated: September 15, 2026
Nontuberculous Mycobacteria Market Research Report Information By Class of Drugs (Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics), By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
Nontuberculous Mycobacteria Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)2.5%
2024 Market Size$ 9.35 Billion
2025 Market Size$ 9.58 Billion
2035 Market Size$ 12.27 Billion
Key Players
Thermo Fisher Scientific
Merck KGaA
Abbott Laboratories
Roche Diagnostics
Bio-Rad Laboratories
Qiagen N.V.
Opportunities
  • Advancements in Diagnostic Technologies
  • Growing Investment in Research and Development
  • Rising Awareness Among Healthcare Professionals
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Class of Drugs (USD Billion)
      1. 4.1.1 Oral Antibiotics
      2. 4.1.2 IV Antibiotics
      3. 4.1.3 Anti Nausea
      4. 4.1.4 Nebulized Antibiotics
    2. 4.2 Healthcare, BY Region (USD Billion)
      1. 4.2.1 North America
        1. 4.2.1.1 US
        2. 4.2.1.2 Canada
      2. 4.2.2 Europe
        1. 4.2.2.1 Germany
        2. 4.2.2.2 UK
        3. 4.2.2.3 France
        4. 4.2.2.4 Russia
        5. 4.2.2.5 Italy
        6. 4.2.2.6 Spain
        7. 4.2.2.7 Rest of Europe
      3. 4.2.3 APAC
        1. 4.2.3.1 China
        2. 4.2.3.2 India
        3. 4.2.3.3 Japan
        4. 4.2.3.4 South Korea
        5. 4.2.3.5 Malaysia
        6. 4.2.3.6 Thailand
        7. 4.2.3.7 Indonesia
        8. 4.2.3.8 Rest of APAC
      4. 4.2.4 South America
        1. 4.2.4.1 Brazil
        2. 4.2.4.2 Mexico
        3. 4.2.4.3 Argentina
        4. 4.2.4.4 Rest of South America
      5. 4.2.5 MEA
        1. 4.2.5.1 GCC Countries
        2. 4.2.5.2 South Africa
        3. 4.2.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Merck KGaA (DE)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Abbott Laboratories (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Roche Diagnostics (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bio-Rad Laboratories (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Qiagen N.V. (NL)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Hologic, Inc. (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Becton, Dickinson and Company (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 GenMark Diagnostics (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY CLASS OF DRUGS
    4. 6.4 CANADA MARKET ANALYSIS BY CLASS OF DRUGS
    5. 6.5 EUROPE MARKET ANALYSIS
    6. 6.6 GERMANY MARKET ANALYSIS BY CLASS OF DRUGS
    7. 6.7 UK MARKET ANALYSIS BY CLASS OF DRUGS
    8. 6.8 FRANCE MARKET ANALYSIS BY CLASS OF DRUGS
    9. 6.9 RUSSIA MARKET ANALYSIS BY CLASS OF DRUGS
    10. 6.10 ITALY MARKET ANALYSIS BY CLASS OF DRUGS
    11. 6.11 SPAIN MARKET ANALYSIS BY CLASS OF DRUGS
    12. 6.12 REST OF EUROPE MARKET ANALYSIS BY CLASS OF DRUGS
    13. 6.13 APAC MARKET ANALYSIS
    14. 6.14 CHINA MARKET ANALYSIS BY CLASS OF DRUGS
    15. 6.15 INDIA MARKET ANALYSIS BY CLASS OF DRUGS
    16. 6.16 JAPAN MARKET ANALYSIS BY CLASS OF DRUGS
    17. 6.17 SOUTH KOREA MARKET ANALYSIS BY CLASS OF DRUGS
    18. 6.18 MALAYSIA MARKET ANALYSIS BY CLASS OF DRUGS
    19. 6.19 THAILAND MARKET ANALYSIS BY CLASS OF DRUGS
    20. 6.20 INDONESIA MARKET ANALYSIS BY CLASS OF DRUGS
    21. 6.21 REST OF APAC MARKET ANALYSIS BY CLASS OF DRUGS
    22. 6.22 SOUTH AMERICA MARKET ANALYSIS
    23. 6.23 BRAZIL MARKET ANALYSIS BY CLASS OF DRUGS
    24. 6.24 MEXICO MARKET ANALYSIS BY CLASS OF DRUGS
    25. 6.25 ARGENTINA MARKET ANALYSIS BY CLASS OF DRUGS
    26. 6.26 REST OF SOUTH AMERICA MARKET ANALYSIS BY CLASS OF DRUGS
    27. 6.27 MEA MARKET ANALYSIS
    28. 6.28 GCC COUNTRIES MARKET ANALYSIS BY CLASS OF DRUGS
    29. 6.29 SOUTH AFRICA MARKET ANALYSIS BY CLASS OF DRUGS
    30. 6.30 REST OF MEA MARKET ANALYSIS BY CLASS OF DRUGS
    31. 6.31 KEY BUYING CRITERIA OF HEALTHCARE
    32. 6.32 RESEARCH PROCESS OF MRFR
    33. 6.33 DRO ANALYSIS OF HEALTHCARE
    34. 6.34 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    35. 6.35 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    36. 6.36 SUPPLY / VALUE CHAIN: HEALTHCARE
    37. 6.37 HEALTHCARE, BY CLASS OF DRUGS, 2024 (% SHARE)
    38. 6.38 HEALTHCARE, BY CLASS OF DRUGS, 2024 TO 2035 (USD Billion)
    39. 6.39 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY CLASS OF DRUGS, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Nontuberculous Mycobacteria Market Segmentation

Nontuberculous Mycobacteria Market By Class of Drugs (USD Billion, 2025-2035)

  • Oral Antibiotics
  • IV Antibiotics
  • Anti Nausea
  • Nebulized Antibiotics
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.